Phase 2
N=15
Letermovir for CMV Prevention After Lung Transplantation
Lung Transplant · CMV
Bottom Line
View on ClinicalTrials.gov: NCT05041426 ↗Enrolled (actual)
15
Serious AEs
26.7%
Results posted
Apr 2026
Primary outcome: Primary: Occurrence of CMV Infection or Disease During Prophylaxis — 0 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Letermovir (Drug); Valganciclovir (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Fernanda P Silveira, MD, MS
- Primary completion
- Mar 2025
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Occurrence of CMV Infection or Disease During Prophylaxis |
— | — |
| PRIMARY Occurrence of CMV Infection or Disease in the 3 Months Following Completion of Prophylaxis |
7 | — |
| SECONDARY Discontinuation Events |
— | — |
| SECONDARY Occurrence of Leukopenia or Neutropenia While on Prophylaxis |
2 | — |
Summary
This is an interventional, open-label, single center, pilot study with historical controls to test the efficacy of letermovir (LET) for the prevention of CMV infection and disease in adult lung transplant recipients (LTRs) with idiopathic pulmonary fibrosis (IPF).
Eligibility Criteria
Inclusion Criteria
- Age ≥18 years on day of signing informed consent
- Listed for lung transplantation (single or double) due to a diagnosis of IPF or receipt of a lung transplant (single or double) for IPF in the 72 hours prior to enrollment
- Have a documented positive serostatus for CMV (CMV IgG seropositive, R+)
- Have a documented negative serostatus for CMV (CMV IgG seronegative, R-) and anticipate receiving or having received a lung allograft from a CMV IgG positive donor, D+). Only participants who are R+ or who are CMV D+/R- will receive intervention. Participants who are CMV D-/R- will be considered screen failures
- Able to travel to UPMC for routine post-transplant visits for a minimum of 15 months after transplantation
- Able to provide informed consent
- Be willing to use a contraceptive method while receiving LET and for at least 90 days following last dose of LET
Exclusion Criteria
- Receipt of a previous solid organ transplant or hematopoietic stem cell transplant
- Multi-organ transplant recipient, i.e., heart-lung or lung-liver
- HIV seropositive
- HCV antibody or HCV RNA positive
- Donor HCV NAT positive
- Anticipated need for use of ganciclovir, valganciclovir, foscarnet, or cidofovir at the time of transplant
- Known or suspected hypersensitivity to LET or acyclovir
- CrCl < 10 ml/min or dialysis on day of transplant
- Child-Pugh Class C severe hepatic insufficiency
- Pregnancy or expected to conceive while on LET and through at least 90 days following cessation of LET
Data sourced from ClinicalTrials.gov (NCT05041426). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.